Healthcare vet readies $100m l/s equity debut
S&P

Healthcare vet readies $100m l/s equity debut

Jonathan Wiley’s Healthcare Innovations Fund targets Q2 launch

A longtime healthcare-focused investment professional is nearing the launch of an AI-driven healthcare-focused long/short equity hedge fund.

It is understood that Jonathan Wiley is plotting the launch of The Wiley Healthcare Innovators Fund.

The fund has already raised more than $60m and is expected to launch in Q2 with around $100m under Wiley Asset Management.

Wiley has targeted several family offices and HNW individuals, with the idea of targeting institutional allocators later on, according to sources familiar.

The fund is targeting to reach around $1bn in AuM within the next five years.

It will primarily focus on US firms and build a portfolio of roughly 50 to 60 positions concentrated in small and mid-cap companies.

Its strategy will aim to focus on addressing longstanding challenges within the healthcare industry, such as an increasing population and decreased number of physicians.

It will use AI as a tool to improve early disease detection, personalized treatment, operational efficiency, cost control and better patient experiences.

Managing the new fund alongside Wiley is Tom D’Amore, who brings hands-on healthcare operational experience across surgical centers, medical technology and healthcare investments.

His work in high-acuity orthopedic surgical settings provides a practical lens for evaluating enabling technologies, orthopedics and AI-driven healthcare companies.

click here

Wiley Asset Management is headquartered in Greenwich, with a satellite office in Miami. The firm also plans to open an office in Arizona in the new future.

Healthcare funds tracked by With returned 36.4% in 2025. The S&P Healthcare and S&P Biotech indices returned 14.6% and 35.9%, respectively.

Wiley also oversees a separate RIA firm named Wiley Capital Partners.

Prior to working on the launch of his own firm, Wiley worked as head of investments at Arch Global Advisors for more than seven years.

Wiley declined to comment.